Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study
| العنوان: | Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study |
|---|---|
| المؤلفون: | P Brossart, Albrecht Lindemann, Volker Diehl, G Hecker, Roland Mertelsmann, Hermann Wagner, Klaus Höffken, D. Voliotis, M Flasshove |
| المصدر: | Cancer immunology, immunotherapy : CII. 37(5) |
| سنة النشر: | 1993 |
| مصطلحات موضوعية: | Interleukin 2, Adult, Male, Cancer Research, Cellular immunity, medicine.medical_treatment, T cell, Lymphocyte, Immunology, Leukocyte Count, Immune system, Neoplasms, medicine, Immunology and Allergy, Humans, Hypersensitivity, Delayed, Lymphocytes, Aged, business.industry, Immunotherapy, Eosinophil, Middle Aged, Cytokine, medicine.anatomical_structure, Oncology, Cytokines, Interleukin-2, Female, business, medicine.drug |
| الوصف: | High-dose interleukin-(IL-2) has been broadly studied in tumour therapy, yet it may be inhibitory to T-cell-dependent immunity. Therefore immune and tumour responses mediated by low-dose IL-2 were studied systematically with respect to the feedback organisation of immune responses. IL-2 was administered once daily at three dose levels: 0.18, 0.9, 4.5 MIU/m2 according to three different schedules requiring subcutaneous (s.c.) injection once weekly (four doses, stratum I), thrice weekly every other day (nine doses, stratum II), or five times weekly every other week (ten doses, stratum III). A total of 46 patients with advanced cancer were randomly assigned to one of the nine treatment groups. Systemic effects were induced at doses as low as 0.18 MIU/m2 IL-2 s.c. as demonstrated from measurable IL-2 serum levels, induction of circulating IL-6, a transient lymphopenia, and stimulation of delayed-type hypersensitivity (DTH) responses of the skin. Analysis of the different IL-2 schedules demonstrated (a) prolonged effects of once-weekly injections on DTH responses, lymphocyte and eosinophil counts, and (b) maximum increase of eosinophil counts and preferential expansion of activated NK cells with repeated injections every 48 h or 72 h (stratum II), while sequential treatment according to stratum III was found to be more potent in increasing the number of activated T cells. A tumour response was observed in 1/15 patients with renal cell carcinoma who experienced more than 50% tumour regression for 8 months; 12 patients had stable disease for 4 months (median). These data demonstrate prolonged immunological effects of ultra-low doses of s. c. IL-2 despite its short half-life. Furthermore, scheduling of IL-2 was found to affect immune responsiveness specifically as demonstrated by the differential effects on natural killer and T cell populations. |
| تدمد: | 0340-7004 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da84d8f362108cf22e6d5bcbf8eba261 https://pubmed.ncbi.nlm.nih.gov/8402734 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....da84d8f362108cf22e6d5bcbf8eba261 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....da84d8f362108cf22e6d5bcbf8eba261 744 3 unknown 744.25927734375 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....da84d8f362108cf22e6d5bcbf8eba261&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da84d8f362108cf22e6d5bcbf8eba261# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22P+Brossart%22">P Brossart</searchLink><br /><searchLink fieldCode="AR" term="%22Albrecht+Lindemann%22">Albrecht Lindemann</searchLink><br /><searchLink fieldCode="AR" term="%22Volker+Diehl%22">Volker Diehl</searchLink><br /><searchLink fieldCode="AR" term="%22G+Hecker%22">G Hecker</searchLink><br /><searchLink fieldCode="AR" term="%22Roland+Mertelsmann%22">Roland Mertelsmann</searchLink><br /><searchLink fieldCode="AR" term="%22Hermann+Wagner%22">Hermann Wagner</searchLink><br /><searchLink fieldCode="AR" term="%22Klaus+Höffken%22">Klaus Höffken</searchLink><br /><searchLink fieldCode="AR" term="%22D%2E+Voliotis%22">D. Voliotis</searchLink><br /><searchLink fieldCode="AR" term="%22M+Flasshove%22">M Flasshove</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Cancer immunology, immunotherapy : CII</i>. 37(5) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 1993 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Interleukin+2%22">Interleukin 2</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Research%22">Cancer Research</searchLink><br /><searchLink fieldCode="DE" term="%22Cellular+immunity%22">Cellular immunity</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22T+cell%22">T cell</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphocyte%22">Lymphocyte</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Leukocyte+Count%22">Leukocyte Count</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+system%22">Immune system</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%22">Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology+and+Allergy%22">Immunology and Allergy</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Hypersensitivity%2C+Delayed%22">Hypersensitivity, Delayed</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphocytes%22">Lymphocytes</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Eosinophil%22">Eosinophil</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Cytokine%22">Cytokine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Eanatomical%5Fstructure%22">medicine.anatomical_structure</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Cytokines%22">Cytokines</searchLink><br /><searchLink fieldCode="DE" term="%22Interleukin-2%22">Interleukin-2</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => High-dose interleukin-(IL-2) has been broadly studied in tumour therapy, yet it may be inhibitory to T-cell-dependent immunity. Therefore immune and tumour responses mediated by low-dose IL-2 were studied systematically with respect to the feedback organisation of immune responses. IL-2 was administered once daily at three dose levels: 0.18, 0.9, 4.5 MIU/m2 according to three different schedules requiring subcutaneous (s.c.) injection once weekly (four doses, stratum I), thrice weekly every other day (nine doses, stratum II), or five times weekly every other week (ten doses, stratum III). A total of 46 patients with advanced cancer were randomly assigned to one of the nine treatment groups. Systemic effects were induced at doses as low as 0.18 MIU/m2 IL-2 s.c. as demonstrated from measurable IL-2 serum levels, induction of circulating IL-6, a transient lymphopenia, and stimulation of delayed-type hypersensitivity (DTH) responses of the skin. Analysis of the different IL-2 schedules demonstrated (a) prolonged effects of once-weekly injections on DTH responses, lymphocyte and eosinophil counts, and (b) maximum increase of eosinophil counts and preferential expansion of activated NK cells with repeated injections every 48 h or 72 h (stratum II), while sequential treatment according to stratum III was found to be more potent in increasing the number of activated T cells. A tumour response was observed in 1/15 patients with renal cell carcinoma who experienced more than 50% tumour regression for 8 months; 12 patients had stable disease for 4 months (median). These data demonstrate prolonged immunological effects of ultra-low doses of s. c. IL-2 despite its short half-life. Furthermore, scheduling of IL-2 was found to affect immune responsiveness specifically as demonstrated by the differential effects on natural killer and T cell populations. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 0340-7004 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da84d8f362108cf22e6d5bcbf8eba261" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da84d8f362108cf22e6d5bcbf8eba261</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/8402734" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/8402734</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....da84d8f362108cf22e6d5bcbf8eba261 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Interleukin 2
[Type] => general
)
[1] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[2] => Array
(
[SubjectFull] => Male
[Type] => general
)
[3] => Array
(
[SubjectFull] => Cancer Research
[Type] => general
)
[4] => Array
(
[SubjectFull] => Cellular immunity
[Type] => general
)
[5] => Array
(
[SubjectFull] => medicine.medical_treatment
[Type] => general
)
[6] => Array
(
[SubjectFull] => T cell
[Type] => general
)
[7] => Array
(
[SubjectFull] => Lymphocyte
[Type] => general
)
[8] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[9] => Array
(
[SubjectFull] => Leukocyte Count
[Type] => general
)
[10] => Array
(
[SubjectFull] => Immune system
[Type] => general
)
[11] => Array
(
[SubjectFull] => Neoplasms
[Type] => general
)
[12] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => Immunology and Allergy
[Type] => general
)
[14] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[15] => Array
(
[SubjectFull] => Hypersensitivity, Delayed
[Type] => general
)
[16] => Array
(
[SubjectFull] => Lymphocytes
[Type] => general
)
[17] => Array
(
[SubjectFull] => Aged
[Type] => general
)
[18] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[19] => Array
(
[SubjectFull] => Immunotherapy
[Type] => general
)
[20] => Array
(
[SubjectFull] => Eosinophil
[Type] => general
)
[21] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[22] => Array
(
[SubjectFull] => Cytokine
[Type] => general
)
[23] => Array
(
[SubjectFull] => medicine.anatomical_structure
[Type] => general
)
[24] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[25] => Array
(
[SubjectFull] => Cytokines
[Type] => general
)
[26] => Array
(
[SubjectFull] => Interleukin-2
[Type] => general
)
[27] => Array
(
[SubjectFull] => Female
[Type] => general
)
[28] => Array
(
[SubjectFull] => business
[Type] => general
)
[29] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => P Brossart
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Albrecht Lindemann
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Volker Diehl
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => G Hecker
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Roland Mertelsmann
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hermann Wagner
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Klaus Höffken
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => D. Voliotis
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => M Flasshove
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 10
[Type] => published
[Y] => 1993
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 03407004
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 37
)
[1] => Array
(
[Type] => issue
[Value] => 5
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Cancer immunology, immunotherapy : CII
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |